Cargando…
Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges
The coronavirus disease (COVID-19) pandemic is sweeping the globe. Even with a number of effective vaccines being approved and available to the public, new cases and escalating mortality are climbing every day. ACE2 (angiotensin-converting enzyme 2) is the primary receptor for the COVID-19 causative...
Autores principales: | Jia, Hongpeng, Neptune, Enid, Cui, Honggang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008810/ https://www.ncbi.nlm.nih.gov/pubmed/33296619 http://dx.doi.org/10.1165/rcmb.2020-0322PS |
Ejemplares similares
-
Smoking and COVID-19: The Real Deal
por: Eakin, Michelle N., et al.
Publicado: (2021) -
Inclusion in the Pulmonary, Critical Care, and Sleep Medicine Physician-Scientist Workforce. Building with Intention
por: Suber, Tomeka L., et al.
Publicado: (2020) -
Challenges and opportunities of online education in dentistry post-COVID-19
por: Quinn, Barry F. A.
Publicado: (2022) -
A historical perspective on ACE2 in the COVID-19 era
por: Bhalla, Vivek, et al.
Publicado: (2020) -
The COVID-19 pandemic - from great challenge to unique opportunity: Perspective(☆)()
por: Duek, Irit, et al.
Publicado: (2020)